SIOP EUROPE

Their core work

SIOP Europe (SIOPE) is the European Society for Paediatric Oncology, a Brussels-based professional association representing the paediatric oncology community across Europe. They work to improve clinical trials infrastructure for children's medicines, advance cancer survivorship care for childhood cancer survivors, and promote standards in paediatric cancer diagnosis and treatment. In H2020 projects, they serve as the voice of the paediatric oncology network — contributing clinical expertise, patient-centred guidelines, and pan-European coordination for childhood cancer research.

What they specialise in

How they've shifted over time

SIOPE's early H2020 work (2018) centred on building foundational infrastructure for paediatric clinical trials and drug development, with strong emphasis on data standards, best practices, and network coordination (c4c, PRIMAGE). From 2019 onward, their focus shifted decisively toward survivorship — what happens to children AFTER cancer treatment — including person-centred care, digital health records, interoperability, and implementation science. This evolution reflects a maturing field moving from treatment-focused research toward long-term care and quality of life for survivors.

SIOPE is moving toward implementation science and digital tools (electronic health records, interoperability) for scaling survivorship care across Europe — expect future work at the intersection of paediatric oncology and e-health.

How they like to work

SIOPE operates exclusively as a participant, never as coordinator — consistent with their role as a professional society that contributes domain expertise rather than managing project logistics. They work in large consortia (99 unique partners across 5 projects), which reflects their function as a pan-European network connector. Working with SIOPE means gaining access to the paediatric oncology community and clinical expertise, but project management responsibility stays elsewhere.

SIOPE has collaborated with 99 unique partners across 21 countries, forming an exceptionally wide network for an organization with only 5 projects. This breadth reflects their role as a pan-European umbrella organization connecting hospitals, universities, and research centres across the continent.

What sets them apart

SIOPE is not a research lab or hospital — it is THE European professional society for paediatric oncology, which gives it a unique convening role that no single institution can replicate. For consortium builders, including SIOPE means instant credibility and access to a continent-wide network of paediatric cancer clinicians and researchers. Their combination of clinical trials expertise with growing survivorship and digital health capabilities makes them an ideal partner for projects that need to bridge research and real-world patient care in children's oncology.

Highlights from their portfolio

• c4c
  By far their largest grant (EUR 1.13M) — a flagship initiative to build pan-European clinical trial networks specifically for children's medicines, running until 2025.
• PanCareSurPass
  Represents their newest strategic direction: scaling a digital Survivorship Passport using electronic health records and implementation science across multiple countries.
• PRIMAGE
  Their entry into computational medicine — combining imaging biomarkers and in-silico modelling for rare childhood cancers (neuroblastoma, DIPG), bridging clinical and digital expertise.